PHOENIX — Eplontersen monotherapy without baseline transthyretin stabilizers preserved the health status of patients with transthyretin amyloidosis with cardiomyopathy out to 140 weeks, a speaker reported.The results of a post hoc analysis of the CARDIO-TTRansform trial of eplontersen (Wainua, Ionis...
Two touch penalties, imaginary cards
22 Feb, 2016
